Skip to main content

Pharmacokinetic profile of a novel slow release preparation of molsidomine

Summary

A novel slow release preparation containing 24 mg molsidomine has been investigated in 6 healthy subjects.

Individual concentration/time-profiles after the tablet showed two separate concentration peaks at 2.2 h and 15.0 h. The relative bioavailability of the slow release preparation in comparison to an aqueous solution of molsidomine was 0.67.

The in vivo dissolution profile revealed either a progressive decrease in dissolution velocity caused by altered physico-chemical conditions in the ileum and the colon or a progressive reduction in the absorption constant. In all subjects deconvolution revealed a punctual increase in absorption about 15 h post-dose, coinciding with the second peak of the concentration/time-profile.

Therapeutic plasma levels of molsidomine (> 5 ng · ml−1 were not maintained over 24 h by this slow release formulation.

This is a preview of subscription content, access via your institution.

References

  1. Unger P, Leone A, Staroukine M, Degré S, Berkenboom G (1991) Hemodynamic response to molsidomine in patients with ischemic cardiomyopathy tolerant to isosorbiode dinitrate. J Cardivasc Pharmacol 18: 888–894

    CAS  Google Scholar 

  2. Unger P, Leone A, Degré S, Berkenboom G (1991) Tolerance to intravenous nitrates. J Cardiovasc Pharmacol 17 [Suppl. 3]: S300-S303

    Google Scholar 

  3. Böhme E, Spies C, Grossmann G (1982) Wirksamer Metabolit von Molsidomin und Stimulation der cGMP-Bildung durch Sydnonimine. In: Bassenge E, Schmutzler H (eds) Molsidomin, neue Aspekte zur Therapie der ischämischen Herzerkrankung. Urban & Schwarzenberg, München Wien Baltimore

    Google Scholar 

  4. Dutot C, Moreau J, Cordonnier P, Spreux-Varoquaux O, Klein C, Ostrowski J, Advenier C, Gärtner W, Pays M (1990) Determination of the active metabolite of molsidomine in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr Biomed Appl 528: 435–446

    CAS  Google Scholar 

  5. Dell D, Chamberlain J (1978) Determination of molsidomine in plasma by high-performance liquid column chromatography. J Chromatogr Biomed Appl 146: 465–472

    Article  CAS  Google Scholar 

  6. Brockmeier D (1986) In vitro/in vivo correlation of dissolution using moments of dissolution and transit times. Acta Pharm Technol 32: 164–174

    CAS  Google Scholar 

  7. Brockmeier D (1984) In vitro-in vivo correlation, a time scaling problem? Evaluation of mean times. Arzneim Forsch/Drug Res 34: 1604–1607

    CAS  Google Scholar 

  8. Brockmeier D, Voegele D, von Hattingberg HM (1983) In vitro - in vivo correlation, a time scaling problem? Basic techniques for testing equivalence. Arzneim Forsch/Drug Res 33: 598–601

    CAS  Google Scholar 

  9. Brockmeier D, Lückel G (1991) (unpublished data)

  10. Bergstrand R, Vedin A, Wilhelmsson C, Peterson LE, Chamberlain J, Dell D, Stevens LA, Ostrowski J (1984) Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study. Eur J Pharmacol 27: 203–208

    CAS  Google Scholar 

  11. Meinertz T, Brandstätter A, Trenk D, Jähnchen E, Ostrowski J, Gärtner W (1985) Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans. Am Heart J 109: 644–648

    Article  CAS  PubMed  Google Scholar 

  12. Ostrowski J, Resak K (1985) Pharmacokinetics of molsidomine in humans. Am Heart J 109: 641–643

    Article  CAS  PubMed  Google Scholar 

  13. Singlas E, Martre H (1983) Pharmacocinetique humaine de la molsidomine. Ann Cardiol Angeiol 32: 503–509

    CAS  Google Scholar 

  14. Voegele D, Ostrowski J, Stauch M, Brockmeier D (1985) In vivo relevance of a controlled oral release system of molsidomine. Pharm Ind 57: 524–527

    Google Scholar 

  15. Wildgrube HJ, Ostrowski J, Chamberlain J, Gärtner W. Stockhausen H (1986) Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers. Arzneimittelforschung Drug res 36: 1129–1133

    CAS  Google Scholar 

  16. Brockmeier D, Grigoleit HG, Leonhardt H (1986) The absorption of piretanide from the gastrointestinal tract is site-dependent. Eur J Clin Pharmacol 30: 79–82

    Article  CAS  PubMed  Google Scholar 

  17. Schuster O, Haertel M, Hugemann B, Gikalov I, Schiemann O, Fenner H (1985) Untersuchungen zu klinischen Pharmakokinetik. Arzneimittelforschung Drug res 35: 760–765

    CAS  Google Scholar 

  18. Staib AH, Beermann D, Harder S, Fuhr U, Liermann D (1989) Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule). Am J Med 87 [Suppl 5A]: 668–698

    Google Scholar 

  19. Staib AH, Loew D, Harder S, Kollath J, Graul EH, Schuster O, Hugemann B (1987) Theophyllin. Absorption in verschiedenen Darmabschnitten. In: Rietbrock N, Woodcock BG, Staib AH, Loew D (eds) Drug absorption at different regions of the human gastro-intestinal tract: methods of investigation and results. Vieweg, Braunschweig Wiesbaden

    Google Scholar 

  20. Staib AH, Rämsch KD, Ahr G, Liermann J, Spichalsky R, Albrecht W (1988) Absorption of nitrendipine and nisoldipine along the intestine of man (HF-capsule study). Naunyn Schmiedebergs Arch Pharmacol 337 [Suppl], R 125

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rietbrock, S., Keller-Stanislawski, B., Thürmann, P. et al. Pharmacokinetic profile of a novel slow release preparation of molsidomine. Eur J Clin Pharmacol 43, 273–276 (1992). https://doi.org/10.1007/BF02333022

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02333022

Key words

  • Molsidomine
  • slow release
  • pharmacokinetics
  • in vitro/in vivo correlation
  • pharmacokinetics
  • healthy volunteers
  • dissolution profile